Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.7% Higher – Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) rose 7.7% on Friday . The company traded as high as $81.47 and last traded at $82.3290. Approximately 363,875 shares were traded during trading, a decline of 60% from the average daily volume of 906,263 shares. The stock had previously closed at $76.45.

Wall Street Analysts Forecast Growth

DNTH has been the topic of a number of research reports. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a report on Monday, March 9th. Wedbush raised their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday. Robert W. Baird lifted their price target on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Finally, Truist Financial lifted their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Up 7.2%

The company has a market capitalization of $4.48 billion, a P/E ratio of -19.87 and a beta of 1.18. The company has a 50-day moving average of $87.15 and a two-hundred day moving average of $64.95.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 8,224 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the sale, the executive vice president directly owned 8,224 shares in the company, valued at $738,844.16. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,121 shares of company stock worth $12,635,454 over the last 90 days. 3.02% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DNTH. Wellington Management Group LLP raised its stake in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after buying an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP raised its stake in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. State Street Corp increased its position in Dianthus Therapeutics by 124.7% during the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after acquiring an additional 836,571 shares during the last quarter. Braidwell LP purchased a new stake in Dianthus Therapeutics during the third quarter valued at $32,859,000. Finally, Polar Capital Holdings Plc purchased a new stake in Dianthus Therapeutics during the third quarter valued at $29,434,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.